The 3rd International Antibody Validation Meeting, September 2018
Antibody Validation: Standards, Policies, and Practices Asilomar, CA USA 2016
1st International Antibody Validation Forum 2014
Recent publications
Tunheim G, Rø GØI, Chopra A, Aase A, Kran AB, Vaage JT, Lund-Johansen F, Hungnes O(2022) Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021 Influenza Other Respir Viruses(in press) DOI 10.1111/irv.13024, PubMed 35770841
Midtvedt K, Vaage JT, Heldal K, Munthe LA, Lund-Johansen F, Åsberg A(2022) Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response Am J Transplant(in press) DOI 10.1111/ajt.17091, PubMed 35533010
Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL(2022) Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy Arthritis Rheumatol(in press) DOI 10.1002/art.42153, PubMed 35507355
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no